These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19834448)

  • 1. The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience.
    Carpenter AP; Pontecorvo MJ; Hefti FF; Skovronsky DM
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):387-93. PubMed ID: 19834448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.
    Lin KJ; Hsu WC; Hsiao IT; Wey SP; Jin LW; Skovronsky D; Wai YY; Chang HP; Lo CW; Yao CH; Yen TC; Kung MP
    Nucl Med Biol; 2010 May; 37(4):497-508. PubMed ID: 20447562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey.
    Hostetler ED; Sanabria-Bohórquez S; Fan H; Zeng Z; Gammage L; Miller P; O'Malley S; Connolly B; Mulhearn J; Harrison ST; Wolkenberg SE; Barrow JC; Williams DL; Hargreaves RJ; Sur C; Cook JJ
    Nucl Med Biol; 2011 Nov; 38(8):1193-203. PubMed ID: 21741254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
    Okamura N; Yanai K
    IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-labeled styrylpyridines as PET agents for amyloid plaque imaging.
    Zhang W; Kung MP; Oya S; Hou C; Kung HF
    Nucl Med Biol; 2007 Jan; 34(1):89-97. PubMed ID: 17210465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain.
    Zhang W; Oya S; Kung MP; Hou C; Maier DL; Kung HF
    Nucl Med Biol; 2005 Nov; 32(8):799-809. PubMed ID: 16253804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of amyloid imaging on drug development in Alzheimer's disease.
    Mathis CA; Lopresti BJ; Klunk WE
    Nucl Med Biol; 2007 Oct; 34(7):809-22. PubMed ID: 17921032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
    de Lartigue J
    Drugs Today (Barc); 2014 Mar; 50(3):219-29. PubMed ID: 24696867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of 3 Novel Tau Radiopharmaceuticals,
    Wong DF; Comley RA; Kuwabara H; Rosenberg PB; Resnick SM; Ostrowitzki S; Vozzi C; Boess F; Oh E; Lyketsos CG; Honer M; Gobbi L; Klein G; George N; Gapasin L; Kitzmiller K; Roberts J; Sevigny J; Nandi A; Brasic J; Mishra C; Thambisetty M; Mogekar A; Mathur A; Albert M; Dannals RF; Borroni E
    J Nucl Med; 2018 Dec; 59(12):1869-1876. PubMed ID: 29728519
    [No Abstract]   [Full Text] [Related]  

  • 11. Validation of a New Imaging Technique Using the Glucose Metabolism to Amyloid Deposition Ratio in the Diagnosis of Alzheimer's Disease.
    Takahashi R; Ishii K; Yokoyama K; For The Alzheimer S Disease Neuroimaging Initiative EY
    Curr Alzheimer Res; 2017; 14(2):161-168. PubMed ID: 27334941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.
    Trembath L; Newell M; Devous MD
    J Nucl Med Technol; 2015 Sep; 43(3):175-84. PubMed ID: 26271806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques.
    Wey SP; Weng CC; Lin KJ; Yao CH; Yen TC; Kung HF; Skovronsky D; Kung MP
    Nucl Med Biol; 2009 May; 36(4):411-7. PubMed ID: 19423009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semi-automatic synthesis and biodistribution of N-(2-
    Wen F; Nie D; Hu K; Tang G; Yao S; Tang C
    BMC Med Imaging; 2017 Apr; 17(1):27. PubMed ID: 28431519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain.
    Zhang W; Oya S; Kung MP; Hou C; Maier DL; Kung HF
    J Med Chem; 2005 Sep; 48(19):5980-8. PubMed ID: 16162001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
    Pascoal TA; Therriault J; Benedet AL; Savard M; Lussier FZ; Chamoun M; Tissot C; Qureshi MNI; Kang MS; Mathotaarachchi S; Stevenson J; Hopewell R; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2020 Sep; 143(9):2818-2830. PubMed ID: 32671408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
    Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
    JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection.
    Fawaz MV; Brooks AF; Rodnick ME; Carpenter GM; Shao X; Desmond TJ; Sherman P; Quesada CA; Hockley BG; Kilbourn MR; Albin RL; Frey KA; Scott PJ
    ACS Chem Neurosci; 2014 Aug; 5(8):718-30. PubMed ID: 24896980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
    Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.